GFAP and multiple sclerosis: In the murine model of multiple sclerosis, we found that MP intranasally administered was able to reduce the inflammatory cytokines as well as the expression of activation markers of glia and astrocytes (Iba1 and GFAP, respectively) and improved the clinical score [27].